We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 478

AbbVie Hit With $150 Million Loss in Low-T Cardiac Trial
  • Baker & Hostetler LLP
  • USA
  • August 15 2017

Jury finds drugmaker responsible for fraudulent misrepresentation


Regeneron Pharmaceuticals, Inc. v. Merus N.V.: The Federal Circuit Revisits the Defense of Inequitable Conduct
  • Baker & Hostetler LLP
  • USA
  • August 4 2017

In Regeneron Pharmaceuticals, Inc. v. Merus N.V., No. 2016-1346, slip op. (Fed. Cir. July 27, 2017) (hereafter, “Slip Op.”), the Federal Circuit seems


Biopsy Rivals Square Off Yet Again in California
  • Baker & Hostetler LLP
  • USA
  • August 1 2017

Guardant Health, Inc., a developer of non-invasive cancer diagnostics, claims to have invented a breakthrough product to identify the genetic progeny


2017 Mid-Year Securities Litigation and Enforcement Highlights
  • Baker & Hostetler LLP
  • USA
  • July 31 2017

The purpose of this report is to provide a periodic survey - in addition to our Practice Team Executive Alerts - on matters we believe to be of


Massachusetts Supreme Court Holds Employee Can Pursue State Law Disability Discrimination Claim for Failure to Accommodate Off-Duty Use of Medical Marijuana
  • Baker & Hostetler LLP
  • USA
  • July 23 2017

On July 17, 2017, the Massachusetts Supreme Judicial Court concluded that an employee could sue her employers for state law disability discrimination


The Federal Circuit Reverses a Hindsight Reconstruction of An Important Pharmaceutical Invention
  • Baker & Hostetler LLP
  • USA
  • July 20 2017

In Millennium Pharmaceuticals v. Sandoz,1 the Federal Circuit reversed the district court’s holding of obviousness of certain claims of


The Supreme Court Delivers a Win for Biosimilar Manufacturers in Sandoz v. Amgen
  • Baker & Hostetler LLP
  • USA
  • June 28 2017

On June 12, 2017, the Supreme Court issued a unanimous opinion in Sandoz v. Amgen, interpreting key provisions of the Biologics Price Competition and


Exaggerated Diagnosis Codes and Inadequate Provider Networks: Allegations of Medicare Advantage Fraud Settled for $32.5 Million
  • Baker & Hostetler LLP
  • USA
  • June 20 2017

The latest settlement involving Medicare Advantage (MA) organizations highlights not only the government’s continuing enforcement focus on Medicare


Health Law Update - June 15 ,2017
  • Baker & Hostetler LLP
  • USA
  • June 15 2017

Senate Republicans continue intra-party discussions on changes to House-passed legislation replacing the Affordable Care Act (ACA), but the lack of


Hospital Seeks Second Opinion on Certifying Class with Uninjured Members
  • Baker & Hostetler LLP
  • USA
  • June 13 2017

Ten years into litigation, a hospital has moved to decertify a class of plaintiffs who claim the hospital’s merger caused them to overpay for medical